• Publications
  • Influence
Interindividual Variability of the Clinical Pharmacokinetics of Methadone
Because of the high morbidity and mortality associated with opioid dependence, it is of major importance that methadone is used at an effective dosage in maintenance treatment: at least 60 mg/day, but typically 80–100 mg/ day.
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
This work aimed to determine the influence of CYP2B6, CYP 2C9, and CYP1C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment.
ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment
The in vivo implication of various cytochrome P450 (CYP) isoforms and of P‐glycoprotein on methadone kinetics is unclear and the genetic factors influencing methadon kinetics and response to treatment are examined.
Stereoselective Block of hERG Channel by (S)‐Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers
This study reports the first genetic factor implicated in methadone metabolism that may increase the risk of cardiac arrhythmias and sudden death and could be reduced by the administration of (R)‐methadone.
ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine
This study has shown for the first time a significant in vivo role of CYP2C19 and the P-gp transporter in the pharmacokinetics of clozapine.
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
  • C. Eap, T. Buclin, +8 authors R. Kerb
  • Chemistry, Medicine
    European Journal of Clinical Pharmacology
  • 28 April 2004
A low oral dose of midazolam can be used to measure the in vivo CYP3A activity, either by the determination of total 1′OH-midZolam/midazol am ratios at 30 min or by thedetermination of midAZolam plasma levels between 1.5 h and 4 h after its administration.
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
It is hypothesize that genetic variability in this gene may contribute to the particularly high, unexplained variability in EFV exposure in individuals with limited CYP2B6 function.
Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals
D dosage adjustment in accordance with the type of polymorphism (CYP2B6, CYP2A6, or CYP3A4) is required in order to maintain EFV within the therapeutic target levels.
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study.
This study is the first to demonstrate that a P-gp polymorphism significantly influences plasma and CSF concentrations of R,S-CIT in depressive patients, therefore possibly influencing the activity of this antidepressant.
Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram.
Significant NPY and CRH changes in CSF following treatment as well as correlations to changes in HAMD support the hypothesis that these two peptides play a role in affective disorders and are markers of therapeutic response.